Loading stock data…
ADPT
$14.27+0.17 (+1.21%)
Market ClosedLast close May 1
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adaptive Biotechnologies Corporation in the Healthcare sector is trading at $14.27. The stock is currently 31% below its 52-week high of $20.76, remaining 4.2% below its 200-day moving average. Technical signals show neutral RSI of 52 and bullish MACD crossover, explaining why ADPT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.27
Potential Upside
5%
Whystock Fair Value$14.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-55.41%
Volume
Today's trading volume
983,568
Recent News
How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions
Adaptive Biotechnologies is back in focus after a fresh look at its valuation nudged the updated fair value estimate to about $20.57, slightly below the prior $20.86 target. Recent Street commentary reflects a split view, with some analysts lifting price targets by about $1, while others question how easily current expectations can be met. As you read on, you will see how these shifting targets and opinions fit together so you can track how the story around Adaptive Biotechnologies is...
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?
This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry partnerships.
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale.
A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements
Why Adaptive Biotechnologies Stock Is Back in Focus Adaptive Biotechnologies (ADPT) is drawing attention after fourth quarter 2025 results topped analyst expectations, supported by its Minimal Residual Disease business and new Pfizer agreements tied to T cell receptor discovery and immune data licensing. See our latest analysis for Adaptive Biotechnologies. The fourth quarter surprise and Pfizer announcements have brought Adaptive Biotechnologies back into the spotlight, with a 19.3% 7 day...